CY1114330T1 - Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου - Google Patents

Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου

Info

Publication number
CY1114330T1
CY1114330T1 CY20131100584T CY131100584T CY1114330T1 CY 1114330 T1 CY1114330 T1 CY 1114330T1 CY 20131100584 T CY20131100584 T CY 20131100584T CY 131100584 T CY131100584 T CY 131100584T CY 1114330 T1 CY1114330 T1 CY 1114330T1
Authority
CY
Cyprus
Prior art keywords
ser
insulin
amino acid
growth factor
medical uses
Prior art date
Application number
CY20131100584T
Other languages
English (en)
Inventor
Teruo Nishida
Makoto Inui
M Nakamura
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1114330T1 publication Critical patent/CY1114330T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Είναι ένα αντικείμενο της εφεύρεσης να εξετάσει την ελαχίστη μονάδα επίδειξης δραστικότητας του παράγοντα-Ι ανάπτυξης που ομοιάζει με ινσουλίνη και να ανακαλύψει μια φαρμακευτική χρήση αυτού στα πεδία οφθαλμολογίας και δερματολογίας. Μια κοινή χορήγηση ενός πεπτιδίου που περιέχει την αλληλουχία αμινοξέος που αντιπροσωπεύεται από Ser-Ser-Ser-Αrg ως την ελαχίστη μονάδα της επίδειξης δραστικότητας του παράγοντα-Ι ανάπτυξης που ομοιάζει με ινσουλίνη και ενός πεπτιδίου που περιέχει την αλληλουχία αμινοξέος που αντιπροσωπεύεται από Phe-Gly-Leu-Μet-ΝΗ2 είναι αποτελεσματική για θεραπεία διαταραχών του κερατοειδούς και μπορεί να προάγει σημαντικά την επούλωση δερματικών τραυμάτων.
CY20131100584T 2001-12-03 2013-07-10 Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου CY1114330T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001368103 2001-12-03
EP02786015.4A EP1462455B1 (en) 2001-12-03 2002-12-03 Ser-Ser-Ser-Arg peptide and medicinal uses thereof

Publications (1)

Publication Number Publication Date
CY1114330T1 true CY1114330T1 (el) 2016-08-31

Family

ID=19177744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100584T CY1114330T1 (el) 2001-12-03 2013-07-10 Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου

Country Status (13)

Country Link
US (3) US7232881B2 (el)
EP (2) EP2172474B1 (el)
JP (1) JP4310588B2 (el)
KR (2) KR100993233B1 (el)
CN (1) CN1263770C (el)
CA (1) CA2469134C (el)
CY (1) CY1114330T1 (el)
DK (1) DK1462455T3 (el)
ES (1) ES2422081T3 (el)
PT (1) PT1462455E (el)
SI (1) SI1462455T1 (el)
TW (1) TWI305778B (el)
WO (1) WO2003048192A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006143601A (ja) * 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
EP1989226A4 (en) * 2006-03-06 2009-11-18 Caregen Co Ltd PEPTIDES HAVING INSULIN-TYPE GROWTH FACTOR ACTIVITY 1 AND USES THEREOF
WO2008086358A1 (en) 2007-01-08 2008-07-17 University Of Southern California Usc Stevens Skin wound healing compositions and methods of use thereof
CL2009000062A1 (es) 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
KR101021197B1 (ko) 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
KR101163171B1 (ko) 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US8207118B2 (en) 2009-07-17 2012-06-26 University Of Southern California Skin wound healing compositions and methods of use thereof
EP2481416A4 (en) 2009-09-25 2013-10-30 Santen Pharmaceutical Co Ltd OPHTHALMIC DROPS
WO2011058982A1 (ja) * 2009-11-11 2011-05-19 国立大学法人山口大学 消化器疾患治療剤
EP2635293B1 (en) * 2010-11-03 2018-04-04 University of Southern California Skin wound healing compositions and methods of use thereof
CN107428805B (zh) * 2015-02-25 2021-01-08 台湾基督长老教会马偕医疗财团法人马偕纪念医院 短合成肽及其治疗和/或预防干眼症的用途
WO2017101748A1 (en) * 2015-12-14 2017-06-22 Yeou-Ping Tsao Short synthetic peptide and uses thereof
KR101869783B1 (ko) * 2016-08-17 2018-06-22 (주)진셀팜 미백 활성이 우수한 펩타이드, 및 이의 용도
US10467113B2 (en) * 2017-06-09 2019-11-05 Hewlett Packard Enterprise Development Lp Executing programs through a shared NVM pool
CN112043818A (zh) * 2020-09-16 2020-12-08 温州医科大学附属第一医院 一种用于皮肤创伤的药物及其制备方法和应用
DE112022005006T5 (de) 2021-10-20 2024-08-08 Tataa Biocenter Ab Verfahren und zusammensetzungen zur detektion mutierter nukleinsäuresequenzen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
JPS6417489A (en) * 1987-07-13 1989-01-20 Hitachi Ltd Extended substrate
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5104787A (en) 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
JPH0525001A (ja) 1991-07-08 1993-02-02 L Lyndstrom Richard 血清不含有医療用溶液および眼組織の品質を高める方法
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
JP4096115B2 (ja) * 2000-08-10 2008-06-04 輝夫 西田 皮膚創傷治癒促進剤
DE60142341D1 (de) * 2000-08-10 2010-07-22 Santen Pharmaceutical Co Ltd Förderer der Hautwundheilung
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途

Also Published As

Publication number Publication date
US7795222B2 (en) 2010-09-14
EP1462455A4 (en) 2008-12-31
US20110059897A1 (en) 2011-03-10
KR100993233B1 (ko) 2010-11-10
EP2172474A1 (en) 2010-04-07
EP2172474B1 (en) 2013-04-17
KR20100002291A (ko) 2010-01-06
US7232881B2 (en) 2007-06-19
ES2422081T3 (es) 2013-09-06
KR20050044630A (ko) 2005-05-12
CA2469134A1 (en) 2003-06-12
JP4310588B2 (ja) 2009-08-12
TWI305778B (en) 2009-02-01
KR100967152B1 (ko) 2010-07-05
US20050009752A1 (en) 2005-01-13
CA2469134C (en) 2013-10-29
US20090005317A1 (en) 2009-01-01
EP1462455B1 (en) 2013-04-10
PT1462455E (pt) 2013-07-09
CN1263770C (zh) 2006-07-12
CN1599748A (zh) 2005-03-23
WO2003048192A1 (fr) 2003-06-12
DK1462455T3 (da) 2013-07-01
AU2002354188A1 (en) 2003-06-17
TW200302108A (en) 2003-08-01
US8183343B2 (en) 2012-05-22
EP1462455A1 (en) 2004-09-29
JP2008163044A (ja) 2008-07-17
SI1462455T1 (sl) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1114330T1 (el) Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
ECSP055712A (es) Combinación sinérgica de proteínas de seda
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
MX9708800A (es) Compuestos biciclicos aromaticos.
ATE399562T1 (de) Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
ES2163805T3 (es) Derivados de acidos benzofurano-acrilicos y su utilizacion como moduladores de los receptores rxrs o rars.
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DK0658553T3 (da) Hidtil ukendte polycykliske aromatiske forbindelser, farmaceutiske præparater og kosmetiske sammensætninger indeholdende di
AU2003292326A1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
KR930019224A (ko) 유산 위험 치료제
Menkes Initial evaluation and management of orthopedic injuries
NO980375L (no) Humant MP52 Arg protein
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
WO2012046922A1 (en) Novel use of antimicrobial peptides in regeneration of skin cells
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
ATE446759T1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
WO2022098944A1 (en) Composition for increasing skin thickness
MXJL03000041A (es) Sistema para antisepsia en cirugia ocular.
RU93031950A (ru) Препарат для лечения ран